CyberKnife radiation for small liver cancer with cirrhosis
Part of Cancer, Digestive system clinical trials.
This trial tests CyberKnife stereotactic body radiation therapy—targeted high-precision radiation—for small hepatocellular carcinoma (liver cancer) in people with decompensated cirrhosis. It may help if other liver cancer treatments aren’t possible, but it has strict safety rules about tumor spread and nearby organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary hepatocellular carcinoma (liver cancer) by a specialist or confirmed by tissue testing
- Your liver cancer is small enough for CyberKnife, and you cannot have—or choose not to have—other treatments like surgery or transplant
- You have decompensated cirrhosis (called Child-Pugh B or C)
- The tumor is not in the portal vein, and there is no cancer outside the liver or in nearby lymph nodes
- Your health is strong enough for treatment (ECOG 0–1), and your blood counts are adequate (platelets and white blood cells meet limits)
- The tumor is at least 5 mm away from key organs like the esophagus, stomach, duodenum, and bowel
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a focused type of radiation (SBRT) given after liver surgery to reduce the chance the cancer comes back, when the tumor was removed with a very small “safety margin.” It compares this approach to standard follow-up and looks at whether it improves outcomes in people with hepatocellular carcinoma.
This study tests proton beam radiation for people with liver cancer that is still inside the liver but cannot be treated with surgery or a small-needle procedure. Proton beams aim to better target the tumor while reducing radiation to nearby organs.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial compares two treatment approaches for large hepatocellular carcinoma (HCC), a type of liver cancer: stereotactic body radiation therapy (SBRT) alone versus SBRT plus TACE, a catheter-based chemo treatment. It may help decide which approach works better for controlling the tumor when surgery isn’t a good option.
This study compares two nonsurgical procedures for liver cancer: stereotactic radiosurgery (focused radiation) and radiofrequency ablation (heat therapy). It is for people whose tumor is in a tricky spot near major blood vessels or other structures, making surgery difficult, and who have not received prior treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.